Non-metastatic castration-resistant prostate cancer, or nmCRPC, is a type of prostate cancer that has not spread to other parts of the body and no longer responds to hormone therapy.*

*Hormone therapy includes drug treatments or surgery to lower testosterone.

Non-metastatic castration-resistant prostate cancerNon-metastatic castration-resistant prostate cancer

Non-metastatic:  
has not spread to other parts of the body

Castration-resistant:
PSA levels rise despite the cancer being treated with hormone therapy

Prostate cancer

nmcrpc infographic

Understanding nmCRPC

Hormone therapy is a mainstay of treatment in prostate cancer. Over time, however, prostate cancer can keep growing even when the amount of testosterone in the body is reduced to very low levels. When this happens, the level of prostate-specific antigen, or PSA, in the bloodstream may rise even if you are on hormone therapy.

Men with nmCRPC may not show symptoms. This makes PSA testing important, both to diagnose nmCRPC and to determine the appropriate next steps for treatment.

Treatment goals in nmCRPC generally include:

  • Delaying the cancer from spreading
  • Extending life
  • Delaying disease-related pain
  • Delaying the need for chemotherapy

Ultimately, your treatment goals are personal decisions to be made between you and your care team.